BCL2L1 and cancer: While efficacy was a secondary endpoint for evaluation in this trial, DT2216 did not demonstrate single-agent activity in patients with different advanced solid tumors, which was not unexpected because most cancer cells require a pro-apoptotic signal triggered by chemotherapy to respond to BCL-XL inhibition [5].